Text size :

Drugs: AIOM oncologists, ‘adequate budgets are needed to guarantee access to new treatments’ (2)

ADNKRONOS

November 9, 2026

(Adnkronos Health) – AIOM – the note details – requests that in all local realities, expenditure for drugs with innovativeness recognized by AIFA, in the indications and periods admitted to dedicated funding, be identified and reported separately and excluded from the containment objectives assigned to oncology structures, within the limits of such funding. Resources dedicated to innovative drugs must find an effective correspondence in corporate budgets, avoiding penalties for centers that appropriately dispense them. This need is particularly relevant when treatments are concentrated in a limited number of authorized centers, as can happen for radioligand therapies: the concentration of cases must be considered in resource allocation. Dedicated funding and related allocations to centers must also be updated when actual needs exceed initial estimates, including for new therapeutic indications or an increase in eligible patients. Furthermore, it is necessary to plan in advance the effects of drugs exiting their innovative status, verifying the capacity of resources allocated to ordinary expenditure and adjusting budgets for treatments that continue to be prescribed. The end of dedicated funding must not compromise the continuity of care.

“We call for a structured dialogue with national institutions, Regions, and corporate managements to share planning criteria based on needs and the value of care – AIOM concludes –. Every resource must be used rigorously, but the progress achieved must become concrete opportunities for all people who can benefit from them. Sustainability is also measured by the ability of our National Health Service to guarantee this access.”

Jiji Press

Related

Page TOP